The gene p53 acts as a tumor suppressor and often is called the ‘guardian of the genome.’ This gene is central to maintaining genomic stability, which prevents mutations from accumulating and leading ...

The study published in NEJM entitled, “Phase 1 Study of Rezatapopt, a p53 Reactivator, in TP53 Y220C-Mutated Tumors,” highlighted the antitumor activity of rezatapopt in heavily pretreated patients ...

A research team at the University of Konstanz, led by toxicologist Ivano Amelio, has demonstrated how differently individual mutations of the tumor suppressor p53 affect pancreatic carcinomas. When ...

Prognostic Value of Histologic Grade and Proliferative Activity in Axillary Node–Positive Breast Cancer: Results From the Eastern Cooperative Oncology Group Companion Study, EST 4189 PURPOSE: To ...

Research from the Federal University of Rio de Janeiro (UFRJ) and the National Institute of Science and Technology for Structural Biology and Bioimaging (INBEB) in Brazil has uncovered a critical ...

Tumor protein P53 (TP53) plays an important role in suppressing the growth of tumors. Mutations in the gene for TP53 can have a disastrous effect, hampering the body's ability to fight tumors and even ...

TP53 mutations are crucial in cancer development and treatment response, influenced by genetic and environmental factors. In CLL and AML, TP53 serves as a significant prognostic marker, affecting ...

No significant financial relationships to disclose. This is an ASCO Meeting Abstract from the 2007 ASCO Annual Meeting. This abstract does not include a full text component.

Investigators at Cold Spring Harbor Laboratory say they've identified a biomarker that can quickly highlight a potentially deadly mutation in p53, a natural tumor suppressor. They found that the ...

Expert breaks down CLL frontline choices, IGHV and p53 risk, and what fits patient life. The treatment landscape for chronic ...